BELITE BIO ($BLTE) posted quarterly earnings results for Q4 2025 on Monday, March 2nd. The company reported earnings of -$0.38 per share, beating estimates of -$0.56 by $0.18. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $BLTE stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BELITE BIO Hedge Fund Activity
We have seen 53 institutional investors add shares of BELITE BIO stock to their portfolio, and 14 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DARWIN GLOBAL MANAGEMENT, LTD. added 3,027,704 shares (+inf%) to their portfolio in Q4 2025, for an estimated $484,311,531
- RTW INVESTMENTS, LP added 715,332 shares (+inf%) to their portfolio in Q4 2025, for an estimated $114,424,506
- MILLENNIUM MANAGEMENT LLC added 538,141 shares (+2594.6%) to their portfolio in Q4 2025, for an estimated $86,081,034
- RA CAPITAL MANAGEMENT, L.P. removed 442,516 shares (-50.6%) from their portfolio in Q4 2025, for an estimated $70,784,859
- PERCEPTIVE ADVISORS LLC added 364,451 shares (+732.0%) to their portfolio in Q4 2025, for an estimated $58,297,581
- VESTAL POINT CAPITAL, LP removed 312,500 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $49,987,500
- POINT72 ASSET MANAGEMENT, L.P. added 281,337 shares (+9075.4%) to their portfolio in Q4 2025, for an estimated $45,002,666
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BELITE BIO Analyst Ratings
Wall Street analysts have issued reports on $BLTE in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Overweight" rating on 01/06/2026
- Mizuho issued a "Outperform" rating on 12/02/2025
- HC Wainwright & Co. issued a "Buy" rating on 12/01/2025
- Cantor Fitzgerald issued a "Overweight" rating on 11/24/2025
To track analyst ratings and price targets for BELITE BIO, check out Quiver Quantitative's $BLTE forecast page.
BELITE BIO Price Targets
Multiple analysts have issued price targets for $BLTE recently. We have seen 6 analysts offer price targets for $BLTE in the last 6 months, with a median target of $188.0.
Here are some recent targets:
- Yi Chen from HC Wainwright & Co. set a target price of $185.0 on 01/28/2026
- Tazeen Ahmad from B of A Securities set a target price of $195.0 on 01/26/2026
- Judah Frommer from Morgan Stanley set a target price of $191.0 on 01/06/2026
- Graig Suvannavejh from Mizuho set a target price of $194.0 on 12/02/2025
- Steve Seedhouse from Cantor Fitzgerald set a target price of $154.0 on 11/24/2025
- Bruce D. Jackson from Benchmark set a target price of $132.0 on 10/31/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
